Amyotrophic Lateral Sclerosis Opportunity Assessment and Forecasts 2019-2024 & 2024-2029 - Focus on US, France, Germany, Italy, Spain, UK, Japan and Canada
Dublin, July 17, 2024 (GLOBE NEWSWIRE) -- The "Amyotrophic Lateral Sclerosis: Opportunity Assessment and Forecast 2019-2029 - Update" report has been added to ResearchAndMarkets.com's offering.
This report covers the 8MM (US, France, Germany, Italy, Spain, UK, Japan and Canada) and provides an Excel-based forecast model for the Amyotrophic Lateral Sclerosis (ALS) market through 2029.
The prevalence of ALS is increasing at a steady rate, in line with population growth in the 8MM, at an annual growth rate (AGR) of 0.79%.The diagnosed prevalent cases of ALS across the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and Canada) are expected to increase from 74,614 cases to 80,483 cases during the forecast period.
The ALS market across the 8MM was valued at $318 million in 2019. Over the 10-year forecast period, the market is projected to grow at a compound annual growth rate (CAGR) of 15%, reaching $1.28 billion by 2029.A key driver of growth for the ALS market will be the launches of 12 pipeline products during the forecast period. These will contribute $375.3 million in sales by 2029, despite most being anticipated to launch towards the latter end of the forecast period.
Key Highlights
Report deliverables include a Pdf report and an Excel-based forecast model
Forecast includes the 8 major markets (8MM)
Forecast covers the period 2019-2029.
2019 base year sales within the ALS market are approximately $318M across the 8MM detailed in this report. The analyst estimates that the ALS market will grow at a compound annual growth rate (CAGR) of 15% to reach $1.28billion by the end of the forecast period.
Reasons to Buy
Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the 8MM ALS therapeutics market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the ALS therapeutics market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Marketed Products
Product Profile: Riutek (riluzole)
Product Profile: Exservan (riluzole oral film)
Product Profile: Tiglutik (riluzole oral suspension)
Product Profile: Radicava (edaravone)
Product Profile: Radicava ORS (edaravone oral suspension)
Product Profile: Qalsody (tofersen sodium)
Product Profile: Relyvrio (phenylbutyrate and taurursodiol)
Late-Stage Pipeline Agents for ALS
Product Profile: Masitinib
Product Profile: NurOwn (debamestrocel)
Product Profile: TUDCA (Tauroursodeoxycholic acid)
Product Profile: MN-166 (ibudilast)
Product Profile: ILT-101 (aldesleukin)
Product Profile: Ulefnersen sodium
Product Profile: Pridopidine hydrochloride
Product Profile: Neuronata-R (lenzumestrocel)
Product Profile: E-0302 (mecobalamin)
Product Profile: SLS-005 (trehalose)
Product Profile: CNM-Au8
Product Profile: PrimeC (celecoxib + ciprofloxacin)
Key Topics Covered:
Abbreviations
Related Reports
Executive Summary
Disease Overview
Overview of ALS
Etiology of ALS
Pathophysiology of ALS
Classification of ALS
ALS SWOT Analysis
Epidemiology
Total Prevalent Cases of ALS, Both Sexes, Ages 40 Years, 2019-29
Age-Specific Trends in the Total Prevalent Cases of ALS, Both Sexes, 2019
Sex-Specific Total Prevalent Cases of ALS, Both Sexes, Ages 40 Years, 2019
Total Prevalent Cases of ALS by Type, Both Sexes, Ages 40 Years, 2019
Diagnosed Prevalent Cases of ALS, Both Sexes, Ages 40 Years, 2019-29
Age-Specific Trends in the Diagnosed Prevalent Cases of ALS, Both Sexes, 2019
Sex-Specific Diagnosed Prevalent Cases of ALS, Both Sexes, Ages 40 Years, 2019
Diagnosed Prevalent Cases of ALS by Type, Both Sexes, Ages 40 Years, 2019-29
Sources and Methodology for ALS Prevalence
Sources and Methodology for Total and Diagnosed Cases of ALS by Type
Sources and Methodology for Diagnosed Prevalent Cases of ALS
Sources and Methodology for Total Prevalent Cases of ALS
Sources and Methodology for Total and Diagnosed Prevalent Cases of ALS by Type
Current Treatment Options
Treatment Paradigm
Unmet Needs and Opportunities
Unmet Needs in ALS
Earlier Diagnosis is Required
Identification of Biomarkers
Continued Need for More Efficacious First-line Treatment Options
Lack of Disease Modifying Therapies
R&D Strategies
R&D Strategies in ALS
Trends in Clinical Trial Design in ALS
Trends in Deal-Making in ALS
Pipeline Assessment
ALS Pipeline Overview
ALS: Clinical Trials (Phase II/III) Overview
Market Outlook
ALS Market Forecast
Market Drivers and Barriers
Appendix
A selection of companies mentioned in this report includes, but is not limited to:
Ionis Pharmaceuticals Inc
Mitsubishi Tanabe Pharma Corp
MediciNova Inc
AB Science SA
Biogen (UK) Ltd
Italfarmaco SA
Sanofi
Iltoo Pharma
Mitsubishi Tanabe Pharma America Inc
Corestemchemon Inc
Seelos Therapeutics, Inc.
Clene Nanomedicine Inc
Amylyx Pharmaceuticals Inc
NeuroSense Therapeutics Ltd
Prilenia Therapeutics Development Ltd
For more information about this report visit https://www.researchandmarkets.com/r/zgxcp2
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900